These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26845939)

  • 1. [A triple combination therapy of simeprevir (SM), pegylated-interferon and ribavirin (PR) with chronic hepatitis C virus genotype 1 infection].
    Suzuki S; Kurosaki M; Izumi N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():248-53. PubMed ID: 26845939
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.
    D'Offizi G; Cammà C; Taibi C; Schlag M; Weber K; Palma M; DeMasi R; Janssen K; Witek J; Lionetti R
    New Microbiol; 2017 Jan; 40(1):19-26. PubMed ID: 28072888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
    Zoulim F; Moreno C; Lee SS; Buggisch P; Horban A; Lawitz E; Corbett C; Lenz O; Fevery B; Verbinnen T; Shukla U; Jessner W
    Virol J; 2018 Jan; 15(1):26. PubMed ID: 29378602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report.
    Igawa T; Fushimi S; Matsuo R; Ikeda F; Nouso K; Yoshino T; Nakatsukasa H
    Clin J Gastroenterol; 2014 Oct; 7(5):465-70. PubMed ID: 26184030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation.
    Miuma S; Ichikawa T; Miyaaki H; Haraguchi M; Tamada Y; Shibata H; Taura N; Soyama A; Hidaka M; Takatsuki M; Eguchi S; Nakao K
    J Interferon Cytokine Res; 2016 Jun; 36(6):358-66. PubMed ID: 27243278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
    Westerhout K; Treur M; Mehnert A; Pascoe K; Ladha I; Belsey J
    J Med Econ; 2015; 18(10):838-49. PubMed ID: 25903830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
    Ogawa E; Furusyo N; Dohmen K; Kajiwara E; Kawano A; Nomura H; Takahashi K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J;
    J Viral Hepat; 2015 Dec; 22(12):992-1001. PubMed ID: 26075320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: a meta-analysis of randomized trials.
    Cui X; Kong Y; Jia J
    Rev Esp Enferm Dig; 2015 Oct; 107(10):591-7. PubMed ID: 26437977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
    Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
    Wei L; Han T; Yang D; Heo J; Shang J; Cheng J; Chen X; Xie Q; Kim JH; Kalmeijer R; Ouwerkerk-Mahadevan S; Hoeben E; Lenz O; Verbinnen T; Sinha R; Li M; Scott J; Peeters M; Witek J;
    J Gastroenterol Hepatol; 2016 May; 31(5):912-20. PubMed ID: 26777137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C].
    Hiramatsu N; Oze T
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():238-42. PubMed ID: 26845937
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
    Ogawa E; Furusyo N; Kajiwara E; Nomura H; Kawano A; Takahashi K; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J
    J Gastroenterol Hepatol; 2015 Dec; 30(12):1759-67. PubMed ID: 26095167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
    Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
    Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
    Taieb V; Pacou M; Ho S; Pettré S; Van Sanden S; Pisini M; Ustianowski A; Mehnert A
    J Med Econ; 2015; 18(10):787-96. PubMed ID: 25934147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
    Izzo I; Zanotti P; Chirico C; Casari S; Villanacci V; Salemme M; Biasi L; Festa E; Castelli F
    Infection; 2016 Dec; 44(6):811-812. PubMed ID: 27311809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.
    Gimeno-Ballester V; Simón MÁ; Trigo C; Mar J; San Miguel R
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1289-1303. PubMed ID: 27626505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vaniprevir with pegylated interferon and ribavirin in treatment for chronic hepatitis C].
    Takehara T
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():254-6. PubMed ID: 26845940
    [No Abstract]   [Full Text] [Related]  

  • 18. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
    Childs-Kean LM; Hand EO
    Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.
    Tahata Y; Hiramatsu N; Oze T; Morishita N; Harada N; Yamada R; Yakushijin T; Mita E; Hagiwara H; Yamada Y; Ito T; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Irishio K; Kato M; Hikita H; Sakamori R; Miyagi T; Yoshida Y; Tatsumi T; Hamasaki T; Hayashi N; Takehara T
    J Gastroenterol; 2016 Mar; 51(3):252-9. PubMed ID: 26223482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
    Hézode C; Fourati S; Chevaliez S; Scoazec G; Soulier A; Varaut A; François M; Ruiz I; Roudot-Thoraval F; Mallat A; Pawlotsky JM
    Clin Infect Dis; 2017 Jun; 64(11):1615-1618. PubMed ID: 28369411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.